New hope for blood cancer patients: experimental pill targets Tough-to-Treat disease
NCT ID NCT07379125
Summary
This early-stage study is testing an experimental oral medication called PMD-026 for people with myelofibrosis, a serious bone marrow cancer. The trial will first find the safest dose and then check if the drug can reduce spleen size and ease symptoms like fatigue and pain. It's designed for patients who cannot take or have not responded to standard JAK inhibitor treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.